SOUTH SAN FRANCISCO, Calif., Jan. 10, 2013 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, provided a corporate update, including a clinical trial enrollment update and overview of 2013 major corporate milestones, in a presentation at the 31 st Annual J.P. Morgan Healthcare Conference in San Francisco. A webcast replay of the presentation, which was delivered today, January 10, at 12:00 PM Pacific Time, is archived on the Sunesis website at http://ir.sunesis.com and will be available for two weeks.
"Last year was a very productive period for Sunesis, with meaningful progress in our vosaroxin studies, including our pivotal, Phase 3 VALOR trial," said Daniel Swisher, Chief Executive Officer of Sunesis. "Looking ahead in 2013, we see a number of value-creating milestones, particularly with the advancement of vosaroxin toward commercialization. It is our goal to see vosaroxin, an unpartnered asset and one of the most advanced and promising therapies in development for AML today, change the global standard of care in this disease. With continued support and enthusiasm from our investigators and stakeholders, as well as a strong balance sheet, we remain well positioned to achieve this goal."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts